Company intelligence / Profile preview

Asepticys

Ownership: Private
Development stage: Other

Overview

Asepticys develops novel chemically unique medical disinfection solutions designed to provide fast and broad-spectrum topical infection control. The company completed clinical trial requirements and filed a 510(k) submission with the US FDA for its Triflect disinfection technology as of April 2019. Clinical results supporting this submission have not been detailed publicly but were sufficient to proceed with regulatory filing.

Therapeutic areas: Infectious Diseases
Modalities: DeviceSmall molecule
Industry: Consumable Medical Devices

Beyond the preview

Go deeper on Asepticys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asepticys.

Explore the full profile